Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
D.Western Therapeutics Institute ( (JP:4576) ) has issued an announcement.
D.Western Therapeutics Institute announced that the FDA has conditionally accepted the new proprietary name ‘Bondlido’ for their lidocaine patch DW-5LBT, which they are developing with the MEDRx Group. This change was necessitated by the FDA’s request due to potential confusion with an existing product name. The new name will be officially approved upon the successful approval of the New Drug Application. The change is not expected to impact the company’s financial forecast for the fiscal year ending December 31, 2025.
The most recent analyst rating on (JP:4576) stock is a Sell with a Yen102.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
More about D.Western Therapeutics Institute
D.Western Therapeutics Institute, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapeutic products. The company, in collaboration with the MEDRx Group, is working on a novel lidocaine patch using proprietary ionic liquid transdermal system technology, aiming to improve upon existing market products.
YTD Price Performance: -46.77%
Average Trading Volume: 1,218,124
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.33B
Find detailed analytics on 4576 stock on TipRanks’ Stock Analysis page.